Abstract
The active peroxisome proliferator-activator receptor ³ (PPAR³) is a potentialtarget for the class of thiazolidinediones (TZD) also known as glitazone, drugs responsible forthis sensitization to insulin in patients with diabetes mellitus type 2. However, its use hasbeen administered with great caution due to its major side effects including weight gain,fluid retention, bone loss, hemodilu…